In a phase 3 trial of 529 adults with early Parkinson disease, tavapadon 5 mg and 15 mg improved MDS-UPDRS parts II+III scores at week 26 vs placebo (differences -11.5 and -12.1 points; both P<.001). Nausea affected 25.4% on tavapadon.
RCTn = 529
Pahwa et al. Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial